bladder carcinoma (Cancer)
Information
- Disease name
- bladder carcinoma
- Disease ID
- DOID:4007
- Description
- "A urinary bladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells." [url:https\://www.mayoclinic.org/diseases-conditions/bladder-cancer/symptoms-causes/syc-20356104]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02439060 | Active, not recruiting | N/A | PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit) | November 25, 2015 | November 25, 2025 |
| NCT05399004 | Active, not recruiting | Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer | September 3, 2019 | September 2024 | |
| NCT03757949 | Active, not recruiting | Phase 3 | Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery | March 5, 2019 | January 1, 2027 |
| NCT02408406 | Active, not recruiting | N/A | PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers | July 7, 2015 | June 4, 2024 |
| NCT02432963 | Active, not recruiting | Phase 1 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | June 14, 2016 | December 31, 2024 |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT00753415 | Completed | Phase 1 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | August 2008 | April 2011 |
| NCT00469066 | Completed | Cone Beam CT Scanning in Lung and Bladder Cancer. | May 2007 | April 2010 | |
| NCT03064308 | Completed | N/A | The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery | June 26, 2017 | July 27, 2018 |
| NCT02355886 | Completed | Phase 2/Phase 3 | Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy | April 22, 2015 | February 28, 2019 |
| NCT03125226 | Completed | N/A | TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer | October 5, 2017 | May 18, 2020 |
| NCT06109857 | Recruiting | Bladder Bank (a Prospective Banking Study) | July 6, 2022 | December 1, 2025 | |
| NCT04410302 | Recruiting | Patient-Derived Xenografts to Reduce Cancer Health Disparities | November 12, 2019 | December 2024 | |
| NCT04459273 | Recruiting | Phase 1 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers | August 27, 2020 | July 1, 2025 |
| NCT04502095 | Recruiting | Phase 4 | Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy | September 2, 2020 | September 2, 2025 |
| NCT05059444 | Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | September 7, 2021 | February 2028 | |
| NCT05480735 | Recruiting | N/A | EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy | August 11, 2022 | October 2025 |
| NCT05519878 | Recruiting | N/A | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | November 29, 2022 | May 25, 2027 |
| NCT05819827 | Recruiting | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics | April 19, 2023 | March 27, 2025 | |
| NCT02202044 | Terminated | N/A | Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection | February 24, 2015 | May 11, 2016 |
| NCT02169284 | Terminated | Phase 2 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | October 1, 2014 | March 30, 2018 |
| NCT05363605 | Terminated | Phase 1/Phase 2 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | April 20, 2022 | September 8, 2023 |
| NCT01245660 | Terminated | Early Phase 1 | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy | January 2011 | October 2011 |
| NCT03549650 | Terminated | Phase 2 | Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms | May 3, 2019 | February 15, 2022 |
| NCT01215136 | Terminated | Phase 2 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | December 2010 | April 24, 2018 |
| NCT02145390 | Terminated | N/A | Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy | January 5, 2016 | April 25, 2017 |
| NCT03324282 | Terminated | Phase 2 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma | February 23, 2018 | January 14, 2022 |
| NCT02457650 | Unknown status | Phase 1 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | April 2015 | December 2019 |
| NCT03824691 | Unknown status | Phase 2 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" | September 25, 2019 | February 2023 |
| NCT02438852 | Withdrawn | Phase 3 | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer | February 25, 2019 | February 25, 2022 |
| NCT05564416 | Withdrawn | Phase 2 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | October 12, 2023 | November 3, 2023 |
| NCT04054752 | Withdrawn | Phase 1 | Vaccine Response With NT-I7 | May 30, 2023 | November 1, 2023 |
- Disase is a (Disease Ontology)
- DOID:11054
- Cross Reference ID (Disease Ontology)
- NCI:C4912
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:269607003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0699885
- Exact Synonym (Disease Ontology)
- carcinoma of urinary bladder
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002862